NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, a global leader in medical cannabis research and production, today unveiled a new product categorization system that simplifies the process of choosing medical cannabis products for patients in Canada. Tilray Profiles are a set of nine easy-to-understand categories that apply to all Tilray products available to patients in Canada, including whole flower, blends, oil drops, and capsules.
“We’ve heard patients request a more streamlined approach to how we categorize medical cannabis products, so we developed Tilray Profiles,” said Philippe Lucas, Vice President of Patient Research and Access at Tilray. “Tilray Profiles provide patients and physicians with the product information they need in a standardized, easily accessible format. The system is especially helpful for those are new to medical cannabis. It helps patients and physicians choose a product based on potency and cannabinoid profile.”
With Tilray Profiles, products are categorized according to the potency of the active cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD). The name of each profile features a letter and a number. The letter indicates the balance of THC and CBD: “T” indicates THC-dominant products, “C” indicates CBD-dominant products, and “TC” indicates a balanced ratio of both cannabinoids. The number following the letter reflects the potency of the product: 100 for low-potency, 200 for medium, and 300 for high. For example, a medium-potency THC-dominant strain of flower would be categorized under the T200 profile.
Each of the nine profiles corresponds to a color, which means that patients can browse the Tilray store and easily determine which products meet their needs. To reflect these changes, Tilray will begin to roll out new packaging for all cannabis products sold in Canada. Strain name and category (sativa, indica, hybrid, and CBD) will continue to be available on the Tilray store and printed on packaging labels for all whole flower cannabis products.
Tilray is a global leader in medical cannabis research and production dedicated to advancing the science, safety, and efficacy of medical cannabis. The company operates one of the largest and most sophisticated federally licensed medical cannabis cultivation facilities in the world, offering a range of products to patients, physicians, pharmacies, governments, hospitals, and researchers in Australia, Canada, the European Union, and Latin America.